AKT1 and pulmonary arterial hypertension: Our findings shed new light on the role of IRF9 in vascular pathology and implicate a newly identified “IRF9- PHB1-AKT axis” in the pathogenesis of PAH, which provides a new alternative target for the molecular therapy of PAH (Figure 7).